Introduction
Contemporary medicine is shifting towards person rather than disease-oriented care. 1 With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050). 2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)-the most frequent indications for dual platelet inhibition or anticoagulation-occur mostly in older patients. 2 -6 There is general agreement that people ≥75 years can be defined 'elderly'; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores. 3,7 -10 Moreover, ageing is a continuous process and life-span expansion is deflating (http://www.nber.org/papers/w18407). For these reasons, a threshold to define 'elderly' has been intentionally avoided in this document. Of note, over one third of patients admitted with acute myocardial infarction (MI) and two thirds dying from MI are over 75 years, but ,7% of patients in ACS trials are reported ≥75 years. 11 Older patients have multi-organ changes, increased
Experimental manipulation of vascular age can delay atherosclerosis, emphasising the relation between ageing and vascular pathology. 20 In the elderly, increasing levels of fibrinogen, factor (F)VII, FVIII, plasminogen activator inhibitor-1, and thrombin-activatable fibrinolysis inhibitor in both genders-and decreased plasminogen in womencreate a prothrombotic environment with reduced fibrinolytic efficiency. 21 -23 Increased concentrations of antithrombotic proteins, such as plasma protein C, antithrombin, and tissue factor pathway inhibitor, are possibly limited to older women. 21, 24, 25 Endothelial dysfunction, inflammation, and an imbalance between oxidative stress and antioxidant defence may play key roles in age-related atherothrombosis. 26 -30 Blood rheology is also impaired with age, mainly via enhanced plasma viscosity and erythrocyte rigidity.
31 Figure 1 Relative benefits of oral anticoagulants vs. no oral anticoagulant (antiplatelet therapies or no antithrombotic therapy) as a function of the CHA 2 DS 2 -VASc and HAS-BLED scores. The clinical benefit of OAC vs. no OAC-expressed as freedom from death, ischaemic stroke, and intracranial haemorrhage-is reflected by the separation of the curves, not only for patients at higher thromboembolic risk (CHA 2 DS 2 -VASc ≥3) but also for patients at higher bleeding risk (HAS-BLED ≥3). Age ≥65 is a key determinant of both embolic and bleeding risk scores. Modified from Friberg et al.
In older people, antithrombotic therapy is complicated by physiological organ changes ( Table 2) . 4, 32, 33 Decreased hepatic blood flow and changes in hepatic size and architecture 34 slow down the activity of cytochrome P450(CYP) 1, 2C4 and 2D6, while CYP3A4 and phase II enzymes are less affected. 34, 35 Kidney function and blood flow are reduced, nephron histology is altered, 36, 37 and body water and lean mass decline with age 32, 38, 39 (Table 2) . Chronically reduced renal function and intercurrent illnesses (e.g. pneumonia or heart failure) may cause an acute decline of creatinine clearance (CrCl) with impact on antithrombotic drugs primarily cleared by the kidney [e.g. low-molecular-weight heparins (LMWHs), fondaparinux, bivalirudin, dabigatran, eptifibatide, and tirofiban]. Renal function in the elderly should be estimated by equations that include age and weight, rather than by serum creatinine alone, which overestimates renal function in this population. 40, 41 Overall, the above changes enhance interindividual variability of response, increase drug toxicity, and potentially attenuate net therapeutic benefits, especially for drugs with a narrow therapeutic index 33, 42 such as warfarin ( Figure 2 ).
43,44

Oral antiplatelet drugs Aspirin
Aspirin is an irreversible platelet cyclooxygenase-1 inhibitor. The most comprehensive information on age-related benefits and risks of low-dose aspirin (defined as 75 -100-mg once daily-o. subjects ,65 years (13% reduction) and ≥65 years (12% reduction); the effect was most marked on nonfatal MI. 3 Because of the higher control rate of vascular events in the older vs. younger population (1.53 vs. 0.40% per year), the absolute benefit of antiplatelet prophylaxis was about three-fold larger in the older population (16 vs. 5 major vascular events prevented per 10 000 subjects treated with aspirin for 1 year). 3 The recent Japanese Primary Prevention 47 Of note, JPPP individuals had a three-fold higher stroke: MI ratio than the 95 000 subjects randomised in previous primary prevention trials, largely explaining the difference between the two analyses. The ongoing Aspirin in Reducing Events in the Elderly trial in a predominantly Western population will provide further information on the benefit -risk balance of low-dose aspirin in men and women .70 years without overt CVD. 48, 49 For secondary prevention, the proportional reduction in vascular events by aspirin is similar to that for primary prevention, but the absolute benefit is an order of magnitude greater in both younger and older patients (see Supplementary material online, Figure S1 ). Besides age being an independent risk factor for major coronary events (rate ratio per decade 1.84, 95% CI 1.74-1.95) and ischaemic stroke (rate ratio 2.46, 95% CI 2.27 -2.65), age is also a risk factor for haemorrhagic stroke (rate ratio 1.59, 95% CI 1.33 -1.90) and major extracranial bleeding (rate ratio 2.15, 95% CI 1.93 -2.39). 3 Consequently, the absolute bleeding hazard of low-dose aspirin is two-to three-fold larger in older than younger people in both genders (see Supplementary material online, Figure S1 ). Moreover, the risk of upper gastrointestinal bleeding increases sharply ≥70 years, 50 especially with a history of gastrointestinal disturbances (see Supplementary material online, Figure S2 ) or concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) 51 related to prevalent osteoarthritic conditions. We recommend long-term low-dose aspirin in elderly patients with overt atherothrombotic disease, unless contraindicated because of allergy, active bleeding or prior ICH. For primary prevention, the benefit -risk balance of treatment is uncertain 52, 53 and is being defined by recently completed or ongoing studies ( Table 3) .
53
Some evidence suggests that low-dose aspirin may reduce the risk of colonic 54 and other cancer 55 which might tip the long-term balance in its favour.
Thienopyridines: ticlopidine, clopidogrel, and prasugrel Pharmacoinvasive strategy: in patients presenting with ST-segment elevation MI within 3 h of onset of symptoms not able to undergo primary PCI within 1 h of first medical contact, a single weight-based 30 -50 mg IV tenecteplase bolus followed by angiography within 6-24 h or by rescue coronary intervention.
therapy; patients .75 years, however, were excluded. Because it is not known whether a clopidogrel load in the elderly receiving thrombolytic therapy is safe, clopidogrel loading cannot be recommended. 52 Optimal duration of dual antiplatelet therapy (DAPT) with contemporary stenting is a matter of debate. 73, 74 The recent DAPT trial randomised 9961 patients (40% ACS) to 12 months or 30 months aspirin plus a thienopyridine followed by aspirin alone; longer compared with shorter DAPT yielded significantly lower rates of ischaemic events but more bleeding complications, with a borderline (P ¼ 0.05) increase of all-cause mortality; among 1032 ≥75 years (11.6%) the results were consistent with the overall findings. 74 TRITON-TIMI 38 randomised 13 608 ACS patients naive for thienopyridines, undergoing PCI and receiving aspirin, to either prasugrel or clopidogrel for a median of 14.5 months. Prasugrel (60-mg load and 10-mg o.d. maintenance), generating a higher plasma active metabolite concentration compared with clopidogrel, significantly reduced the rate of cardiovascular death, MI, or stroke vs. clopidogrel (HR 0.81, 95% CI 0.73 -0.90; P , 0.001). 60 The 1769 patients ≥75 years (13%) had a 6% RR reduction with prasugrel, compared with a 25% RR reduction in those ,65 years (interaction P not significant) (see Supplementary material online, Table S1 ). Table S1 ). Among 4033 NSTE-ACS patients randomised to receive prasugrel either at initial diagnosis or after angiography (median 4.3 h later), earlier dosing led to a 1.9-fold significant increase in major bleeding without ischaemic benefits; the findings were consistent in the 715 ≥75 years. 77 In the elderly, we recommend clopidogrel on top of aspirin for up to 1 year after elective PCI. After ACS, clopidogrel rather than prasugrel or ticagrelor should be considered if bleeding risk is high. A loading dose of clopidogrel with fibrinolysis is not recommended for those .75 years. Following ACS, the use of prasugrel is cautioned in patients ≥75 years and is contraindicated for those with prior stroke/TIA; for NSTE-ACS, prasugrel should not be given before angiography, regardless of age; when prasugrel is deemed necessary in the elderly, a 5-mg rather than 10-mg o.d. maintenance should be considered, because bleeding rates with 5-mg are similar to those seen in younger patients receiving 10-mg, without apparent loss in efficacy; the 5-mg dose however has not been investigated in the setting of coronary stenting ( Table 3) .
Ticagrelor
Ticagrelor is a reversibly binding inhibitor of the platelet P2Y 12 receptor, recommended in preference to clopidogrel in patients with NSTE-ACS (regardless of management strategy) or STEMI managed with primary PCI. 75, 78 The parent drug and its active metabolite are cleared mainly through hepatic metabolism and biliary excretion. 61, 79 The PLATO trial randomised 18 624 ACS patients, nearly all receiving aspirin, to either ticagrelor or clopidogrel for up to 12 months; 2878 (15%) were ≥75 years. 80 The significant reductions in ischaemic events and total mortality found in the overall trial with ticagrelor (180-mg load and 90-mg b.i.d. maintenance) vs. clopidogrel were consistent among older and younger patients (P for interaction ≥0.56). Given the higher risk of older patients, the absolute mortality reduction with ticagrelor vs. clopidogrel was numerically greater in those ≥75 years (9.8 vs. Table S1 ). The advantage of ticagrelor over clopidogrel in elderly patients is corroborated by the amplified benefits of ticagrelor in patients with renal dysfunction. 81 Prehospital ticagrelor has been compared with ticagrelor administered at angiography (median 31 min later) in 1862 STEMI patients; earlier dosing was not associated with significant differences in rates of persisting ST-segment elevation or TIMI 3 flow before primary PCI, or in non-CABG-related major bleeding at 48 hrs and 30 days; the findings were consistent in different age groups. 82 Rates of 30-day definite stent thrombosis were lower for the prehospital-treated group (0.2 vs. 1.2%, P ¼ 0.02; no age analysis, given small number of events). 82 Although ticagrelor is contraindicated in those with prior ICH, it lowered mortality compared with clopidogrel in those with prior ischaemic stroke/TIA (no age analysis, given small subgroup). 83 Ticagrelor significantly increases the frequency of dyspnoea and sinoatrial pauses vs. clopidogrel, without age -treatment interaction; 80,84 its use is cautioned in patients with sinoatrial disease who do not have a permanent pacemaker 84 and in those with a history of asthma and/or chronic obstructive pulmonary disease (COPD) (http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_Product_Information/ human/001241/WC500100494.pdf). We recommend ticagrelor in elderly ACS patients in the absence of contraindications such as active bleeding or prior ICH, with caution in those presenting advanced sinoatrial disease not treated with a permanent pacemaker and in those with a history of asthma and/or COPD ( Table 3) . We recommend great caution in the elderly owing to the 2-to 3-fold increased risk of ICH and to amplification of the age-related increased risk of major bleeding. The drug cannot be used in those with prior ischaemic stroke/ TIA or ICH ( Table 3) .
Intravenous antiplatelet agents: glycoprotein IIb/IIIa inhibitors and cangrelor
See Supplementary material online, Appendix, Table 3 , and Table S1 .
Oral anticoagulants Vitamin K antagonists
Older age increases the risk of major haemorrhage with vitamin K antagonist (VKA). 85 Of 99 628 emergency hospitalisations for adverse drug events among older adults in the USA, warfarin was implicated in approximately one third of them. 86 Annual rates of major haemorrhage during warfarin therapy, derived from randomised trials in AF, range from 1.7 to 3.0% for patients ,75 years and from 4.2 to 5.2% for those ≥75 years. 87 The higher bleeding risk in the elderly is multifactorial and includes age-and warfarin-specific factors. Older individuals require significantly lower VKA doses to achieve the same target INR as younger individuals, partly explaining the greater early bleeding hazard. 88 In addition, elderly patients are slower to normalise an elevated INR, with resultant longer exposure to risk-laden levels above the target range. 12 89 (see Supplementary material online, Table S2 ). Vitamin K antagonists are also indicated in the secondary prevention of venous thromboembolism (VTE); further details on VKA and non-VKA oral anticoagulants (NOACs) in the elderly are below. Thus, older age per se is not a contraindication to the use of VKA in AF or VTE, but lower doses and tighter monitoring may be required (Table 3) .
Direct thrombin inhibitors: dabigatran Nonvalvular atrial fibrillation
The phase III randomised trial comparing dabigatran with warfarin in 18 113 nonvalvular AF patients found no significant age interaction for the efficacy outcome of stroke/SE; the latter outcome was Table S2 ). The risk of ICH was consistently reduced by dabigatran vs. warfarin, irrespective of age and dose. 66 Gastrointestinal bleeds instead were more common with dabigatran 150-mg b.i.d. compared with warfarin. Given that elderly patients often have impaired renal function, particular attention in elderly patients is required, considering dabigatran's 80% renal clearance. 90 Still, the efficacy of both doses of dabigatran was consistent with the overall trial irrespective of kidney function. 91 The drug is contrain- Table 3) .
Dabigatran for venous thromboembolism
See Supplementary material online, Appendix, and 68 Intracranial haemorrhage and fatal bleeding occurred less-but gastrointestinal bleeding morefrequently with rivaroxaban vs. warfarin. There was no significant interaction between treatment and age for the primary outcome of stroke/SE, nor for major and non-major clinically relevant bleeding (see Supplementary material online, Table S2 ).
94
In ARISTOTLE, 9 31% of the 18 201 AF patients with at least one additional risk factor for stroke were ≥75 years; apixaban 5-mg b.i.d.
[2.5-mg b.i.d. if any two of three conditions were present: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL (133 mmol/L)] was superior in preventing stroke/SE, caused significantly fewer major, total, or ICH, and resulted in lower mortality across all age groups vs. warfarin (P for interaction .0.10 for all) (see Supplementary material online, Table S2 ). Results were consistent for the 13% of patients ≥80 years. 95 Gastrointestinal bleeds
were not more common with apixaban compared with warfarin. The advantages concerning major bleeding with apixaban were amplified in patients with renal dysfunction. 96 Apixaban 5-mg b.i.d., or 2.5-mg b.i.d. as above, was also compared with aspirin (81-324-mg o.d.) in 5599 nonvalvular AF patients considered unsuitable for VKA. 8 Rates of stroke/SE were markedly reduced with apixaban vs.
aspirin (HR 0.45, 95% CI 0.32-0.62; P , 0.001), with no significant differences in major bleeding or ICH and with consistent results across age strata (see Supplementary material online, Table S2 ).
In ENGAGE AF-TIMI 48, 69 40% of 21 105 patients at moderateto-high thromboembolic risk were ≥75 years; both 60-and 30-mg o.d. edoxaban regimens were non-inferior to warfarin in preventing stroke/SE and caused significantly less overall major bleeding and ICH. Gastrointestinal bleeds were more common with the higher edoxaban dose vs. warfarin. The 30-mg edoxaban regimen was associated with higher rates of ischaemic stroke but lower rates of all-cause death and gastrointestinal bleeding compared with warfarin. Results were consistent in different age subgroups (see Supplementary material online, Table S2 ). The FDA has approved 60-mg o.d. edoxaban for stroke prevention in AF for individuals with CrCl 50 -95 and 30-mg o.d. for individuals with CrCl 15 -50 mL/min; based on subgroup analyses, the FDA signals reduced efficacy in patients with excellent renal function related to lower drug levels. Edoxaban has received approval recommendation from the EMA Committee for Medicinal Products for Human Use.
In elderly nonvalvular AF patients with CrCl .15 mL/min, we recommend oral FXa inhibitors in preference to warfarin, given the lower incidence of ICH, the favourable overall efficacy and safety, and the lack of routine monitoring ( Table 3) . Attention towards a limited number of drug -drug interactions, 97 possible gastrointestinal bleeds, and dose reductions in patients with impaired kidney function are warranted, although the prevalent excretion route of these FXa blockers is liver metabolism, bile, and faeces (50-75%, depending on specific agent).
Direct FXa inhibitors in ACS and venous thromboembolism
See Supplementary material online, Appendix, Table 3 , and Table S3 .
Parenteral anticoagulants Unfractionated and low-molecular-weight heparins
Unfractionated heparin (UFH) is not renally cleared and is a reasonable option for CrCl ,30 mL/min. However, over or underdosing, related to changes in bioavailability, inflammatory state, cardiac output, and body weight, can arise rapidly and frequently in older people. The superior bioavailability and overall efficacy of LMWHs, such as enoxaparin, have prompted preferential use of s.c. LMWHs over IV UFH. Randomised trials in the setting of DVT/PE, ACS, thrombolysis, primary or elective PCI, haemodialysis, and AF have mostly shown comparable or better efficacy of LMWH vs. UFH, with overall comparable bleeding rates. 98 -101 Low-molecularweight heparins are primarily eliminated through the kidneys. Age, gender, body weight, and creatinine are all taken into consideration in the Cockcroft Gault equation to calculate CrCl, which is a valuable guide to down-titrate weight-adjusted LMWHs (see . Accumulation may occur after repeated injections but is less common during the first 24 -36 h and does not exist with a single IV injection, as used in PCI.
In SYNERGY, 25% of 9977 ACS patients randomised to enoxaparin vs. UFH were ≥75 years. 102 Age-related analyses suggested caution in subjects ≥75 years because of excessive severe bleeding with enoxaparin. 102 A pooled analysis of ASSENT-3 and -3PLUS
in STEMI patients treated with tenecteplase found a significant interaction (P ¼ 0.001) among age, sex, and enoxaparin for ICH: in women .75 years, ICH occurred in 10/183 on enoxaparin (5.5%) vs. 1/185 (0.5%) on UFH (P ¼ 0.005). 103 ExTRACT-TIMI 25 randomised 20 500 STEMI patients receiving fibrinolysis to UFH or enoxaparin, which was dose-adjusted for age and renal function: 30-mg IV bolus and 1-mg/kg s.c. every 12 h for age ,75 years; no IV bolus and 0.75-mg/kg s.c. every 12 h for age ≥75 years; 24 h dosing interval if CrCl ,30 mL/min. There was consistent benefit and no excess bleeding with enoxaparin vs. UFH among the 2500 patients ≥75 years. 70, 104 Thus, UFH remains an option for parenteral anticoagulation in elderly patients with severe renal impairment. For enoxaparin, we recommend o.d. s.c. dosing when CrCl is ,30 mL/min and reduction from 1 to 0.75 mg/kg without an initial bolus for age ≥75 years, especially with concomitant fibrinolysis (Table 3) . A single IV injection of LMWH, as used in PCI, does not need dose adjustment.
Fondaparinux
Fondaparinux is a synthetic, indirect FXa inhibitor, eliminated mainly by the kidney, that is contraindicated for CrCl ,20 mL/min. 105 OASIS-5 randomised 20 078 patients with NSTE-ACS to 2.5 mg s. Given the lower bleeding rates and overall equal efficacy vs. the comparators, we recommend fondaparinux in NSTE-ACS patients and in STEMI patients not undergoing primary PCI; for non-primary PCI, adjunctive UFH/bivalirudin needs to be added; fondaparinux is contraindicated in severe renal failure (CrCl ,20 mL/min); a 1.5-mg o.d. dose may be considered for patients with CrCl 20-50 mL/min ( Table 3) .
Bivalirudin
See Supplementary material online, Appendix, Table 3 , and Table S4 .
Fibrinolytic therapy for ST-elevation myocardial infarction and pulmonary embolism
See Supplementary material online, Appendix, and Table 3 .
How to prevent and manage bleeding in the elderly
Since the elderly per se are at increased bleeding risk during antithrombotic therapy, and bleeds are associated with increased mortality in both the short and long term, it is essential to consider preventive measures. 109 
Duration and intensity of therapy
For ACS, regardless of management strategy, dual oral antiplatelet therapy is currently recommended for 1 year. 75, 78 Bleeding is increased by prasugrel or ticagrelor instead of clopidogrel, although ticagrelor is associated with reduced mortality vs. clopidogrel even in those ≥75 years. 60, 62, 80 In stable patients, the precise duration of DAPT is decided on the basis of stent type and individual bleeding risk. 110 In elderly ACS patients that require long-term anticoagulation, DAPT may be shortened by the use of bare metal instead of drug-eluting stents in case of PCI. 14, 111, 112 Prolonged triple antithrombotic therapy should be avoided; in one phase II safety trial, aspirin was omitted with significant reduction in bleeding, 113 although evidence for omitting aspirin rather than clopidogrel is limited; beyond the first 12 months, in patients with no recurrent ischaemic event, it is recommended to avoid antiplatelet drugs in favour of oral anticoagulation.
111,112
Surgery Surgery should be avoided in elderly patients requiring both anticoagulant and antiplatelet therapy, unless absolutely necessary, or at least postponed until antithrombotic therapy can be stopped or reduced, given the perisurgical bleeding hazards. 114 
Access site during percutaneous coronary intervention
Arterial access bleeding is frequent and a radial rather than a femoral approach for angiography/PCI is recommended, accepting the occasional need to cross-over to the femoral access and the observation that the benefits of the radial approach seem to emerge with greater experience of centres.
-120
Use of proton pump inhibitors
European Society of Cardiology guidelines recommend a PPI with DAPT to reduce gastrointestinal bleeding events. 75, 78, 121 It is not known whether a PPI is beneficial in elderly patients receiving a single antithrombotic drug, given lack of adequately sized randomised trials with major gastrointestinal bleeding as primary endpoint. With clopidogrel, PPIs with low CYPC19 inhibitory capacity (e.g. pantoprazole) are preferred. 121 
Other measures
These include blood pressure control, avoidance, or limited use of other drugs that enhance bleeding (e.g. NSAIDs, steroids), close monitoring of INR during VKA therapy, avoidance of heavy alcohol intake.
Management of bleeding
As in younger patients, management includes identification and treatment of the bleeding source, haemostatic intervention (manual, endoscopic, and surgical), discontinuation of anti-thrombotic drugs (partial or complete), replacement therapy, and antidotes if available, depending on bleeding severity and risk of ischaemic recurrence. 14, 52, 78, 97 Transfusions are recommended in haemodynamically unstable patients or with haematocrit ,25% or haemoglobin ,7 g/dL. 14, 122 Knowledge of the mechanism of action, half-life and elimination route of the anticoagulant/antiplatelet agent, as well as timing of last administration and kidney function, are important for optimal management.
When to stop, when to restart treatment
Minor or nuisance bleeding and minor interventions (cutaneous, percutaneous, dental, and endoscopy) should not trigger interruption of appropriately prescribed antithrombotic therapy. 14, 52 Discontinuation may be required for major bleeding, after a stroke, or because of surgery in a critical/closed space (posterior eye, spinal, and intracranial) or at high haemorrhagic risk (major, reconstructive, and prostatic surgery). 52 Non-VKA oral anticoagulants may be resumed 3, 6, and 12 days after a small, moderate, or large ischaemic stroke, respectively. 97 After ICH, resuming antithrombotic therapy should be considered with great caution, especially after lobar bleeds that have higher recurrence rates than deep cerebral bleeds; 123 left atrial appendage occlusion may be an alternative.
97,124
Case illustrations Computerized tomography shows a small-to-moderate occipital ICH, and echocardiography a well-functioning prosthesis, preserved LV function, and enlarged left atrium. Vitamin K antagonist and aspirin are discontinued; vitamin K, fresh frozen plasma, PPI, and furosemide are administered IV. Surgical drainage is not performed. Spontaneous gradual recovery, neuroimaging at 2 weeks, and discussion with the 'brain team' lead to resumption of VKA after 3 weeks. The patient is discharged with instructions to maintain the INR 2.5, avoid NSAIDs/antiplatelets, and monitor BP. The decision on whether or not and when to restart VKA is based on limited/ imprecise data with no randomised controlled trial evidence. Non-VKA oral anticoagulants are associated with fewer ICH vs. warfarin but are not recommended for patients with mechanical heart valves.
Summary and future challenges
The number of elderly individuals exposed to one or more antithrombotic treatments is growing. Effective therapies generally provide larger absolute benefits in older than in younger patients despite a higher risk of bleeding. To avoid older people being denied antithrombotic drugs because of unjustified concerns, or conversely being inappropriately overtreated, this patientoriented consensus document has focused on age-specific risks and benefits of antithrombotic drugs tested in phase III trials and provides recommendations summarised in Table 3 . Elderly patients are underrepresented in trials and accurate information on the benefit -risk balance of most antithrombotic drugs is limited. There is a need to define/refine therapy for older groups to maximize benefits and minimise risks. The lack of interaction between current risk scores and the effects of various treatments means that improved methods of estimating risks and benefits of different interventions in specific groups and settings are urgently needed. Because trials to test antithrombotic regimens may be difficult in the elderly owing to inadequate sample sizes and logistical barriers (e.g. reduced cognitive function and mobility), mechanistic studies are being considered. 125 The limits of current evidence provide the rationale for undertaking, if not appropriately powered trials, at least mechanistic studies to guide decisions in older patients based on clinical and laboratory characteristics. 45, 126 
